FDA clears at‑home tDCS

The FDA has cleared Flow Therapeutics’ Flow‑100, described as the first at-home transcranial direct‑current stimulation device for major depression, with availability expected in the U.S. in the second half of 2026. Coverage listed this clearance alongside other early‑2026 psychiatry developments such as AI therapy use and phase‑3 psychedelic data. The device was presented as part of a trend toward more medical treatments designed for home use. (patientcareonline.com) (hcplive.com)